TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype

Journal of Cellular Physiology

Volumn 225, Issue 3, 2010, Pages 682-691

  Storci, Gianluca ^a,b   Sansone, Pasquale ^a,b   Mari, Sara ^a   D'Uva, Gabriele ^a,b   Tavolari, Simona ^b   Guarnieri, Tiziana ^b   Taffurelli, Mario ^b   Ceccarelli, Claudio ^a,b   Santini, Donatella ^a,b   Chieco, Pasquale ^a   Marcu, Kenneth B ^a,c   Bonafè, Massimiliano ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CD24 ANTIGEN; ESTROGEN RECEPTOR ALPHA; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; PROTEIN P53; TRANSCRIPTION FACTOR SLUG; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CALCIUM BINDING PROTEIN; CD44 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; SERRATE PROTEINS; SIGNAL PEPTIDE; SNAIL FAMILY TRANSCRIPTION FACTORS; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER RELAPSE; CANCER STEM CELL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; INFLAMMATION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; DRUG EFFECT; FEMALE; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD44; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NF-KAPPA B; PHENOTYPE; RECOMBINANT PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 77957735709     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22264     Document Type: Article

References (62)

1. al-Hajj M, Wicha MS, Benito-Hernandez a, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl acad Sci USa 100: 3983-3988.
2. Balkwill F. 2009. Tumour necrosis factor and cancer. Nat Rev Cancer 9: 361-371. Review.
3. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev a, Weinberg RA. 2008. an embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507.
4. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès a, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt a, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin a, de Thé H. 2007. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4: e90.
5. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, Chaffanet M, Maraninchi D, Viens P, Birnbaum D. 2009. How different are luminal a and basal breast cancers? Int J Cancer 124: 1338-1348.
6. Cao Y, Luo JL, Karin M. 2007. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl acad Sci USa 104: 15852-15857.
7. Cariati M, Naderi a, Brown JP, Smalley MJ, Pinder SE, Caldas C, Purushotham aD. 2008. alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 122: 298-304.
8. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F. 2006. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284.
9. Cole SW. 2009. Chronic inflammation and breast cancer recurrence. J Clin Oncol 27: 3418-3419.
10. Dickins Ra, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNa precursors. Nat Genet 37: 1289-1295.
11. Dickson BC, Mulligan aM, Zhang H, Lockwood G, O'Malley FP, Egan SE, Reedijk M. 2007. High-level JaG1 mRNa and protein predict poor outcome in breast cancer. Mod Pathol 20: 685-693.
12. Dong R, Wang Q, He XL, Chu YK, Lu JG, Ma QJ. 2007. Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-alpha-induced epithelial-mesenchymal transition of MCF7 cells. Braz J Med Biol Res 40: 1071-1078.
13. Dontu G, abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. 2003. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253-1270.
14. Dhasarathy a, KajITA M, Wade PA., 2007. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alphA. Mol Endocrinol 21, 2907-2918.
15. Eliasson P, Jönsson JI. 2010. The hematopoietic stem cell niche: Low in oxygen but a nice place to be. J Cell Physiol 222: 17-22.
16. Estrach S, ambler Ca, Lo Celso C, Hozumi K, Watt FM. 2006. Jagged 1 is a beta-catenin target gene required for ectopic hair follicle formation in adult epidermis. Development 133: 4427-4438.
17. Fulford LG, Easton DF, Reis-Filho JS, Sofronis a, Gillett CE, Lakhani SR, Hanby A. 2006. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49: 22-34.
18. Görlach a, Bonello S. 2008. The cross-talk between NF-kappaB and HIF-1alpha: Further evidence for a significant liaison. Biochem J 412: 17-19.
19. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, Bondesson M. 2005. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9: 617-628.
20. Hammond EM, Giaccia aJ. 2006. Hypoxia-inducible factor-1 and p53: Friends, acquaintances, or strangers? Clin Cancer Res 12: 5007-5009. Review.
21. 2. Lymphat Res Biol 5: 159-168.
22. Hayes MJ, Thomas D, Emmons a, Giordano TJ, Kleer CG. 2008. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. Clin Cancer Res 14: 4038-4044.
23. Hehner SP, Hofmann TG, Dröge W, Schmitz ML. 1999. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163: 5617-5623.
24. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg a, Hegardt C. 2008. CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 17: R53.
25. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. 2008. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl acad Sci USa 105: 5774-5779.
26. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl acad Sci USa 95: 7987-7992.
27. Ikuta T, Kawajiri K. 2006. Zinc finger transcription factor Slug is a novel target gene of aryl hydrocarbon receptor. Exp Cell Res 312: 3585-3594.
28. Laffin B, Wellberg E, Kwak HI, Burghardt RC, Metz RP, Gustafson T, Schedin P, Porter WW. 2008. Loss of singleminded-2s in the mouse mammary gland induces an epithelial-mesenchymal transition associated with up-regulation of slug and matrix metalloprotease 2. Mol Cell Biol 28: 1936-1946.
29. Lerebours F, Vacher S, andrieu C, Espie M, Marty M, Lidereau R, Bieche I. 2008. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8: 41.
30. Liu R, Wang X, Chen GY, Dalerba P, Gurney a, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF. 2007. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226.
31. Livasy Ca, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. 2006. Phenotypic evaluation of the basal-like subtype of invasive breast carcinomA. Mod Pathol 19: 264-271.
32. Mani Sa, Guo W, Liao MJ, Eaton EN, ayyanan a, Zhou aY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
33. Mantovani a, allavena P, Sica a, Balkwill F. 2008. Cancer-related inflammation. Nature 454: 436-444. Review.
34. McCarthy a, Savage K, Gabriel a, Naceur C, Reis-Filho JS, ashworth A. 2007. a mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 211: 389-398.
35. Moreno-Bueno G, Cubillo E, Sarrió D, Peinado H, Rodríguez-Pinilla SM, Villa S, Bolós V, Jordá M, Fabra a, Portillo F, Palacios J, Cano A. 2006. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res 66: 9543-9556.
36. O'Brien J, Schedin P. 2009. Macrophages in breast cancer: Do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J Mammary Gland Biol Neoplasia 14: 145-157. Review.
37. Olivotto E, Borzi RM, Vitellozzi R, Pagani S, Facchini a, Battistelli M, Penzo M, Li X, Flamigni F, Li J, Falcieri E, Facchini a, Marcu KB. 2008. Differential requirements for IKKalpha and IKKbeta in the differentiation of primary human osteoarthritic chondrocytes. arthritis Rheum 58: 227-239.
38. Paddison PJ, Cleary M, Silva JM, Chang K, Sheth N, Sachidanandam R, Hannon GJ. 2004. Cloning of short hairpin RNas for gene knockdown in mammalian cells. Nat Methods 1: 163-167.
39. Penzo M, Massa PE, Olivotto E, Bianchi F, Borzi RM, Hanidu a, Li X, Li J, Marcu KB. 2009. Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1. J Cell Physiol 218: 215-227.
40. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan a, Ulrich CM. 2009. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27: 3437-3444.
41. Ponti D, Costa a, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti Ma, Daidone MG. 2005. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506-5511.
42. Pratt Ma, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C, Lau R, Niu MY. 2009. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 28: 2710-2722.
43. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG, Erdman SE. 2006. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 66: 7395-7400.
44. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. 2005. High-level coexpression of JaG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537.
45. Rius J, Guma M, Schachtrup C, akassoglou K, Zinkernagel aS, Nizet V, Johnson RS, Haddad GG, Karin M. 2008. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alphA. Nature 453: 807-811.
46. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M. 2007A. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117: 3988-4002.
47. Sansone P, Storci G, Pandolfi S, Montanaro L, Chieco P, Bonafé M. 2007b. The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxiA. Br J Cancer 96: 1302-1308.
48. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano a, Moreno-Bueno G, Palacios J. 2008. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997.
49. Schwartz DR, Wu R, Kardia SL, Levin aM, Huang CC, Shedden Ka, Kuick R, Misek DE, Hanash SM, Taylor JM, Reed H, Hendrix N, Zhai Y, Fearon ER, Cho KR. 2003. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 63: 2913-2922.
50. Shaulian E, Zauberman a, Ginsberg D, Oren M. 1992. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNa binding. Mol Cell Biol 12: 5581-5592.
51. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H. 2006. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59.
52. Shipitsin M, Campbell LL, argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, anderson KS, Harris LN, Garber JE, Richardson aL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. 2007. Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
53. Simon MC, Keith B. 2008. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9: 285-296.
54. Storci G, Sansone P, Trere D, Tavolari S, Taffurelli M, Ceccarelli C, Guarnieri T, Paterini P, Pariali M, Montanaro L, Santini D, Chieco P, Bonafé M. 2008. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 214: 25-37.
55. Van Laere SJ, Van der auwera I, Van den Eynden GG, van Dam P, Van Marck Ea, Vermeulen PB, Dirix LY. 2007. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MaPK hyperactivation. Br J Cancer 97: 659-669.
56. Warren Ma, Shoemaker SF, Shealy DJ, Bshar W, Ip MM. 2009. Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice. Mol Cancer Ther 8: 2655-2663.
57. Weisz L, Damalas a, Liontos M, Karakaidos P, Fontemaggi G, Maor-aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M. 2007. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67: 2396-2401.
58. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. 2009. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15: 416-428.
59. Xiao Y, Ye Y, Yearsley K, Jones S, Barsky SH. 2008. The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. am J Pathol 173: 561-574.
60. Zhang Y, Ting aT, Marcu KB, Bliska JB. 2005. Inhibition of MaPK and NF-kappa B pathways is necessary for rapid apoptosis in macrophages infected with YersiniA. J Immunol 174: 7939-7949.
61. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. 2008A. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 111: 419-427.
62. Zhou C, Nitschke aM, Xiong W, Zhang Q, Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, Weldon CB, Schiff R, McLachlan Ja, Beckman BS, Wiese TE, Nephew KP, Shan B, Burow ME, Wang G. 2008b. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 10: R105.